TITLE

Vascular Sex Hormone Receptors and their Specific Modulators in the Management of Postmenopausal Cardiovascular Disease

AUTHOR(S)
do Nascimento, Graciliano R. A.; Barros, Yaskara V. R.; Wells, Amanda K.; Khalil, Raouf A.
PUB. DATE
November 2009
SOURCE
Current Hypertension Reviews;2009, Vol. 5 Issue 4, p283
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Cardiovascular disease (CVD) is more common in men and postmenopausal women than premenopausal women, suggesting vascular benefits of female sex hormones. Studies on the vasculature have identified estrogen receptors ERa, ER� and a novel estrogen binding membrane protein GPR30, that mediate genomic and/or non-genomic effects. Estrogen promotes endothelium-dependent relaxation by inducing the production/activity of nitric oxide, prostacyclin, and hyperpolarizing factor, and inhibits the mechanisms of vascular smooth muscle contraction including [Ca[sup 2+]][sub i], protein kinase C, Rho kinase and mitogen-activated protein kinase. Additional effects of estrogen on the cytoskeleton, matrix metalloproteinases and inflammatory factors contribute to vascular remodeling. However, the experimental evidence did not translate into vascular benefits of menopausal hormone therapy (MHT), and the HERS, HERS-II and WHI clinical trials demonstrated adverse cardiovascular events. The discrepancy has been partly related to delayed MHT and potential changes in the vascular ER amount, integrity, affinity, and downstream signaling pathways due to the subjects' age and preexisting CVD. The adverse vascular effects of MHT also highlighted the need of specific modulators of vascular sex hormone receptors. The effectiveness of MHT can be improved by delineating the differences in pharmacokinetics and pharmacodynamics of natural, synthetic, and conjugated equine estrogens. Estriol, "hormone bioidenticals" and phytoestrogens are potential estradiol substitutes. The benefits of low dose MHT, and transdermal or vaginal estrogens over oral preparations are being evaluated. Specific ER modulators (SERMs) and ER agonists are being developed to maximize the effects on vascular ERs. Also, the effects of estrogen are being examined in relation to the levels and effects of other sex hormones including progesterone and androgens. Thus, the experimental vascular benefits of estrogen can be translated to the outcome of MHT in postmenopausal CVD, as more specific modulators of sex hormone receptors become available and are used at the right dose, route of administration and timing, depending on the subject's age and preexisting cardiovascular condition.
ACCESSION #
48308251

 

Related Articles

  • Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease. Masood, Durr-e-Nayab; Roach, Emir C.; Beauregard, Katie G.; Khalil, Raouf A. // Current Drug Metabolism;Oct2010, Vol. 11 Issue 8, p693 

    No abstract available.

  • Circulating and Vascular Bioactive Factors During Hypertension in Pregnancy. Tanbe, Alain F.; Khalil, Raouf A. // Current Bioactive Compounds;Mar2010, Vol. 6 Issue 1, p60 

    Normal pregnancy is associated with significant vascular remodeling in the uterine and systemic circulation in order to meet the metabolic demands of the mother and developing fetus. The pregnancy-associated vascular changes are largely due to alterations in the amount/activity of vascular...

  • Combined lack of estrogen receptors α and β affects vascular iNOS protein expression. Liang, M.; Ekblad, E.; Lydrup, M.-L.; Nilsson, B.-O. // Cell & Tissue Research;Jul2003, Vol. 313 Issue 1, p63 

    Endothelial and vascular smooth muscle cells express both estrogen receptor (ER) α and β. Recent findings indicate that vascular ERβ and ERα may substitute for one another. Here, we investigate vascular morphology, contractility and protein expression in intact aorta from adult (4...

  • Large angioleiomyoma, rich of mast cell and sex hormone receptor expression. Hayashi, Masaru; Tomita, Shigeki; Fukasawa, Ichio; Inaba, Noriyuki // Archives of Gynecology & Obstetrics;Feb2009, Vol. 279 Issue 2, p193 

    Angioleiomyoma is a rare benign solitary tumor, arising from the vascular smooth muscle. This tumor usually occurs in the subcutis of extremities, uncommonly in abdomen, often presents as a small (<2 cm) and is treated with excision. We report an extremely rare case of unusually large...

  • Cannabinoids and Cardiovascular Disease: The Outlook for Clinical Treatments. Ashton, John C.; Smith, Paul F. // Current Vascular Pharmacology;Jul2007, Vol. 5 Issue 3, p175 

    Cannabinoid drugs exert their effects primarily through activation of cannabinoid CB1 and CB2 receptors. Both CB1 and CB2 receptors have been implicated in a number of cardiovascular processes, including vasodilation, cardiac protection, modulation of the baroreceptor reflex in the control of...

  • Arginase inhibitor attenuates pulmonary artery hypertension induced by hypoxia. Chu, YanBiao; XiangLi, XiaoYing; Niu, Hu; Wang, HongChao; Jia, PingDong; Gong, WenBin; Wu, DaWei; Qin, WeiDong; Xing, ChunYan // Molecular & Cellular Biochemistry;Jan2016, Vol. 412 Issue 1/2, p91 

    Hypoxia-induced pulmonary arterial hypertension (HPAH) is a refractory disease characterized by increased proliferation of pulmonary vascular smooth cells and progressive pulmonary vascular remodeling. The level of nitric oxide (NO), a potential therapeutic vasodilator, is low in PAH patients....

  • P190 Deficiency of non-endothelial eNOS causes hypertension in mice. Suvorava, T; Stegbauer, J; Thieme, M; Pick, S; Rump, C; Fischer, JW; Hohlfeld, T; Kojda, G // Cardiovascular Research;Jul2014, Vol. 103 Issue suppl_1, pS33 

    Purpose: Despite irrefutable role of endothelial nitric oxide synthase (eNOS) in vascular smooth muscle tone, its contribution to the regulation of blood pressure has been proven mainly either by the global eNOS-deficiency or by the use of unspecific NOS-inhibitors. To distinguish the relevance...

  • cGMP-Dependent Protein Kinase in Regulation of the Pulmonary Circulation. Yuansheng Gao; Raj, J. Usha // Current Respiratory Medicine Reviews;2006, Vol. 2 Issue 4, p373 

    Cyclic GMP-dependent protein kinase (PKG) plays a central role in the responses of the pulmonary vasculature to nitric oxide, nitrovasodilators, and natriuretic peptides. In mammalian cells, PKG is present in two forms, PKG I and PKG II, and the type I isoform is the primary enzyme involved in...

  • Genetic modifiers of hypertension in soluble guanylate cyclase α1-deficient mice. Buys, Emmanuel S.; Raher, Michael J.; Kirby, Andrew; Mohd, Shahid; Baron, David M.; Hayton, Sarah R.; Tainsh, Laurel T.; Sips, Patrick Y.; Rauwerdink, Kristen M.; Yan, Qingshang; Tainsh, Robert E. T.; Shakartzi, Hannah R.; Stevens, Christine; Decaluwé, Kelly; Rodrigues-Machado, Maria da Gloria; Malhotra, Rajeev; Van de Voorde, Johan; Wang, Tong; Brouckaert, Peter; Daly, Mark J. // Journal of Clinical Investigation;Jun2012, Vol. 122 Issue 6, p2316 

    Nitric oxide (NO) plays an essential role in regulating hypertension and blood flow by inducing relaxation of vascular smooth muscle. Male mice deficient in a NO receptor component, the α1 subunit of soluble guanylate cyclase (sGCα1), are prone to hypertension in some, but not all, mouse...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics